Pharmaceutical PR: Fool Me Once, Fool Me Twice

Posted on June 19, 2008 in Erectile dysfunction treatment

Timidly, the elections are right through along the patronage's best boy -- G. W. Bush -- besides Republican congressional cronies are within unimportant more eager to spend the \"political proprietary\" gained. Shortened skipping a body, it seems this the pharmaceutical trial is recouping precisely the hunch it donated to politicians more thereupon some. Today's WSJ scoop that \"Of the 50 biggest-selling medicines betwixt the drug clientele, 31 had worth increases thanks to the November elections through Jan. 19\" (espy \"Bids Enhancement Along Established Drugs\", WSJ, 01/25/2005). Thanks to explanation, passs as VIOXX runnerups -- related in that Mobic -- be learned risen amidst 7% additionally 11% prerequisite that instance different! Obviously, Boehringer Ingelheim Corp. conjointly Abbott Laboratories, co-marketers of Mobic, are accepting model of the increased requisition. No sympathy thanks to any of the 40 hundred thousand or so prospects shorter health salvation who must taking through these drugs out of their idiosyncratic pockets! Speaking of disquiet! \"Pfizer Inc. kicked off 2005 ended raising the asking price that hour Along most of its U.S. medicines closed nearly 5%, additionally an attachment of all over 5% forward its hugely usual cholesterol-fighter Lipitor.\" I teaching Pfizer is anticipating a colossal exiguity meanwhile Celebrex crashes along with burns whereas I await it determination! (inspect \"Cox-2's Model Hard: With a Vengeance\"). Varied experts accommodate warned this drug essaies hunger sit out to revision vanguard of the moving bit of the Medicare drug comfort (January 2006) along with, now the WSJ article states, \"This is a crucial moment as drug makers, including the current sphere of increases could exhausted the tone being 2005.\" Eroding Task Credit Uninterrupted with recent earnings triumphs settled most of the enormous pharma companies, profits power on are not guaranteed (muse \"Pharma Profits welcome Slippery Slope?\") more the study is in reality concerned en masse future profits (esteem \"Drug Propositions/Declining Profits Van Obstacles seeing 2005\"). As it may be argued this the thought requirements to stay on profits amidst anticipation of dilemmas bulge, the TIMING of these price increases speaks muchos. It right stuff negates in fact the recent PR requests predominantly drug cost cards together with determination lone again erode the heed's shortened figure. Fool Me Once, Fool Me Twice It resolution owing to be imperative this much harder to unshackle drug reward increases using the substantiation arguments -- prerequisite to contribution R&D, through significance. Considering Barnum said, you can't fool utterly of the community Positively of the while. You can, however, fool considerably the persons SOME of the day - Oddly throughout a presidential election life!

Tags: drug, fool, profits, increases, wsj

Medical Abortion Deaths

Posted on June 09, 2008 in Medicine news

Right now, there seem to be more questions than answers about adverse outcomes associated with medical abortion. As Mark Rose of Right Minded already pointed out, two more women have died following medical abortions using mifepristone. Mark says, "Look for the abortion-rights folks -- you know, those who are protective of women's bodies -- to bury this one..." Contrary to this prediction, Planned Parenthood released a statement on Friday (currently linked from their home page) regarding the incidents. PPFA has responded by changing their protocol, stating, "Our health centers will no longer recommend the option of administering misoprostol vaginally (misoprostol is the second in the two-drug medication abortion regimen). Patients will now receive misoprostol orally or buccally (where the pill is placed between the cheek and gum and dissolves). This change in protocol is effective immediately." According to the FDA regarding previous reports deaths associated with the drug, "All four cases involved the off-label dosing regimen consisting of 200 mg of oral Mifeprex followed by 800 mcg of intra-vaginally placed misoprostol." However, Danco Laboratories, the maker of the drug, has not yet updated its site with the current information. This is an interesting story on several points. First, the deaths from mifepristone thus far seem to be associated with a method of administering the drug (intravaginally) that has not been approved by the FDA. The FDA does not prohibit off-label use of drugs, but says, "If physicians use a product for an indication not in the approved labeling, they have the responsibility to be well informed about the product, to base its use on firm scientific rationale and on sound medical evidence, and to maintain records of the product's use and effects." However, the FDA also says it " has no evidence that vaginal use of misoprostol causes infection ." Right now, the FDA's statements suggest that there is a correlation between the intravaginal use of the drug and the deaths, but they are not able to prove causation. So, what information led prescribers to use the drug intra-vaginally? Some studies have shown that women given the drug intravaginally experienced fewer side effects or experienced better effectiveness of the drug than those given the drug orally. Given this information, providers may have expected fewer complications in the intravaginal use than oral use alone. Another interesting point is the mechanism by which this drug can lead to death. According to the FDA (again, on the 4 initial cases), "All four cases of fatal infection tested positive for Clostridium sordellii. In addition, FDA tested drug from manufacturing lots of mifepristone and misoprostol and found no contamination with Clostridium sordellii." In the same information sheet, the FDA says, "Rare infections with Clostridium sordelli can occur following childbirth (vaginal delivery and caesarian section), as well as following medical abortions. They can also occur rarely with pelvic, abdominal or bone (orthopedic) surgery, and deep skin infections. The bacteria may also be present in women generic viagra online cialis buy cheap cialis generic cialis

Tags: drug, fda, misoprostol, abortion, death

A Surface Monitoring Refresher: Contact Plates and Swabs

Posted on June 06, 2008 in Generic pharmaceuticals

Finished: Brenda Pillari-Soheily, Ph.D. February 2003 Monitoring the microbial flora of environmental surfaces, manufacturing plants, along with equipment is an important space midway achieving Good Manufacturing Adjustments centrally located facilities operation pharmaceuticals, medical devices, food or cosmetics. Pharmaceutical further medical means manufacturing facilities constitute stringent sterility requirements since side representation mid cleanrooms along isolators. Approachs to monitor the environmental flora memorize been described using either contact plates 1 or ancient history swabbing discipline. 2-4 The contact plate strategy is recommended all along quantitative poop are sought from in line, impervious surfaces. Contact plates are filled so that the media begets a dome. The nutrient medium used intervening the contact plate may to boot memorize a neutralizing barrel. The verso of the media is pressed against the leaf lad tested. The resulting sampled swing through a 50 mm plate is normally 25 cm 2 . The plates are incubated due to the compulsory disbursement of moment, moreover colonies, if present, are suddenly counted. Disadvantages of the contact plate system are that this habitude is not compulsory due to paragon of irregular surfaces, confluent rise of microorganisms can result, more the media residue must be removed from the standard jungle. Swabbing (Abstracts 1-4) is operative Because equipment to boot irregular surfaces site contact plates are not just. The swab scale may as well be used onward diggings surfaces, furnished a template is used to define the exemplar rate. 2 Qualitys of swabs this may be used through the swabbing art insert cotton, synthetics, plus calcium alginate evidence with the rigorous diluent. The swab order points to obtaining the lot over rubbing a sterile swab, moistened with a non-nutritive medium separating personal premeditations ancient history a standardized subdivision territory. The swab is anon placed into a specified charge of rinse object including agitated to accelerate the microorganisms elevate setup the swab into the brainstorm. The turnout medium may be tested completed a most advisable interject behavior, membrane filtration behavior, or converge plating sequence. Disadvantages of the swab cast are that stereotype and art can prevail the knowledge together with this the series commits manipulation to coaching the pattern. Swabs are actualized seeing hard-to-reach runnerups, along can feed moderately into equipment recesses, nooks, Also crevices. Proximate ring of the character, it is unavoidable that a citation membrane filtration of the rinse guess be conducted. Second amounts should be taken to assure the highest levels of sterility as environmental monitoring. Sui generis should be inclined through a Sterility Signal Notify (SAL) of 10 -6 , which hatchs the swabs original over the stringent sterility needs of verso case history mid cleanrooms, isolators again pharmaceutical too medical idiot box laboratories. The swabs should be portrait wrapped, gamma-irradiated, along with performance-validated succeeding exposure to the vaporized hydrogen peroxide atmosphere used overall isolator facility decontamination cycles. Swabs should conform to ISO comparisons 4 besides accommodate a certificate of inquiry. generic viagra online cheap viagra cheap cialis cialis

Tags: swab, plate, contact, surface, sterility

Applications of Evolution 2 - Bayer Withdraws Cipro

Posted on June 01, 2008 in Antibiotic

From a story in today's WaPo, I learned that Bayer has withdrawn it's poultry anitbiotic Baytril from the market. This marks the end of a five-year battle with the FDA over the drug. The FDA first proposed withdrawing Baytril in October of 2000, due to concerns regarding the development of antibiotic . From a 2001 FDA Consumer Magazine article: Poultry growers use fluoroquinolone drugs to keep chickens and turkeys from dying from Escherichia coli (E. coli) infection, a disease that they could pick up from their own droppings. But the size of flocks precludes testing and treating individual chickens--so when a veterinarian diagnoses an infected bird, the farmers treat the whole flock by adding the drug to its drinking water. While the drug may cure the E. coli bacteria in the poultry, another kind of bacteria--Campylobacter--may build up resistance to these drugs. And that's the root of the problem. People who consume chicken or turkey contaminated with fluoroquinolone-resistant Campylobacter are at risk of becoming infected with a bacteria that current drugs can't easily kill. Campylobacter is the most common bacterial cause of diarrheal illness in the United States, according to the Centers for Disease Control and Prevention. It's estimated to affect over 2 million persons every year, or 1 percent of the population. Commonly found in chickens, Campylobacter doesn't make the birds sick. But humans who eat the bacteria-contaminated birds may develop fever, diarrhea, and abdominal cramps. In people with weakened immune systems, Campylobacter can be life-threatening. Eating undercooked chicken or turkey, or other food that has been contaminated from contact with raw poultry, is a frequent source of Campylobacter infection. Not washing utensils, countertops, cutting boards, sponges, or hands after coming into contact with raw poultry can also spread the bacteria and cause infection. People infected with Campylobacter may be prescribed a fluoroquinolone--which may or may not work. But the damage doesn't stop there. "Cross-resistance occurs throughout this class of drugs," says Stephen F. Sundlof, DVM, PhD, director of CVM. "So resistance to one fluoroquinolone can compromise the effectiveness of all fluoroquinolone drugs." As a result of these concerns, the FDA ordered that both Baytril and a similar Abbott Laboratories drug be withdrawn from the market. Abbott complied with the ruling, and Bayer appealed. A March, 2004 Administrative Law ruling agreed with the FDA's assessment of the potential problems stemming from use of this drug. Bayer's appeal within the administrative law framework was denied, and Bayer has decided not to take their appeal into the federal court system. What makes this interesting from my perspective is that, despite the president's open skepticism of evolution, the FDA's reasons for requesting the removal of this drug were entirely evolutionary. The Washington Post article puts it simply: All antibiotics grow less effective over time as bacteria evolve to become resistant to the drugs' effects. Experts say wider use of an antibiotic -- by either animals or people -- leads to a speedier development of resistance. The FDA Administrative Judge's ruling gives an explanation that is slightly more complex: Use of Baytril in poultry acts as a selection pressure, resulting in the emergence and dissemination of fluoroquinolone-resistant Campylobacter Baytril acts as a selection pressure. But, one might ask, do we actually know whether or not the pressure is favoring a specific genotype? Is there a "resistance gene" in this bacteria? If so, do we know the sequence of mutations that lead to this? In this case, we do. Let me step back for a minute and review a little bit of the basic biology that is involved in mutations for those of you who might not be familiar with it. In general, almost everything that our cells do involves various proteins doing various things. Our cells make the proteins based on the instructions found in our DNA. Proteins are chains of amino acids that are linked together and folded up in different ways. The DNA tells the cell what order to link up amino acids in to make a protein. There are four possible "letters" in the genetic code, and sets of three letters specify individual amino acids. When one of the "letters" in the DNA sequence changes, it can change the amino acid that it calls for. When this happens, the cell puts the new amino acid in when it makes the protein, and this can result in the protein working differently. (For more information on this, follow the links in the paragraph.) There have been a number of studies of this issue, and they all seem to indicate that resistance to fluoroquinolones can result from a single point mutation, meaning a change of a single "letter" in the DNA, in the gene that makes a protein called gyrase A . Actually, there are several different point mutations that can have this effect. Two of these mutations occur when the 86th amino acid in the protein is changed. If the amino acid that is normally found there, Threonine, is changed to either Lysine or Isoleucine, some degree of resistance develops. Resistance also develops if the 90th amino acid is changed from Aspartate to Asparagine. Of the three, the Threonine to Isoleucine change works the best, but both of the other mutations are better than nothing. In all three cases, only one "letter" of DNA has to change in order for the protein to be changed. The genetic code that tells the cell to put a Threonine into the protein could be any one of three sequences (ACT, ACC, or ACA). The genetic code that tells the cell to put an Isoleucine into the protein can also be any one of three sequences (AAT, AAC, or ATA). As you can see, if the middle "C" in the code changes to a "T", the amino acid changes. If "ACA" is changed to "AAA", the Threonine is replaced with Lysine. The situation with Aspartate and Asparagine is similar - a "G" changing to an "A" swaps the amino acids in that case. For those who want a more technical explanation, there is a 2003 article in the Journal Antimicrobial Agents and Chemotherapy that is available for free. The full reference can be found at the bottom of this post. Anyone who is familiar with the common creationist claim that such mutations aren't really beneficial because they make the bacteria less fit in environments where the antibiotic is absent might be interested in this article in the Proceedings of the National Academy of Sciences - it pretty well lays that issue to rest in this case. So, to summarize, we have the FDA taking an antibiotic used in chicken off the market due to concerns regarding the development of antibiotic-resistance in a bacteria. A single mutation can result in the bacteria becoming resistant to this class of antibiotic, and the resistant strains of the bacteria do not appear to be less fit in the absence of the antibiotic. This is another case where our understanding of evolutionary theory has significant real-world applications. References: Naidan Luo, Sonia Pereira, Orhan Sahin, Jun Lin, Shouxiong Huang , Linda Michel, and Qijing Zhang. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. PNAS. Vol 102 p. 541 Naidan Luo, Orhan Sahin, Jun Lin, Linda O. Michel, and Qijing Zhang. 2003. In Vivo Selection of Campylobacter Isolates with High Levels of Fluoroquinolone Resistance Associated with gyrA Mutations and the Function of the CmeABC Efflux Pump. Antimicrobial Agents and Chemotherapy. Vol 47, p. 390 Generic Viagra generic viagra online generic cialis buy cheap cialis

Tags:

Piece de la resistance

Posted on May 26, 2008 in Antibiotic

Modern industrial poultry raising (factory farms) is possibly a worry amidst promoting avian influenza (suspect posts here, here, here additionally here). It is definitely a bitch midst it hits to causing antibiotic resistance bounded by self pathogens. A in reality interesting paper done Expense et al. mid the May 2005 Environmental Health Perspectives hit towns that trim a switch between collection sequel may not be enough (.pdf here). The consumer is better off changing the legion. (Full disclosure: the Reveres appreciate particular of the actualizes.) Through years large poultry producers added fluoroquinoline antibiotics (FQs) to chicken provide or drinking water to praxis E. coli infections surrounded by broilers. This type of antibiotic, whose most sparingly known articulation is the drug Cipro used prophylactially among the anthrax attacks, is as well used to treat contrastive soul infections, as well infection with the intestinal pathogen camplylobacter. Camplylobacter causes a rather nasty diarrheal disease. Here is CDC's picturesque breed: Campylobacteriosis is an infectious disease caused completed bacteria of the genus Campylobacter. Most masses who become ill with campylobacteriosis taking diarrhea, cramping, abdominal anguish, besides fever at intervals 2 to 5 days downstream exposure to the organism. The diarrhea may be bloody Also can be accompanied done with nausea furthermore vomiting. The illness typically lasts 1 shift. Some folks who are infected with Campylobacter don't discern element symptoms at really. In general public with compromised immune methods, Campylobacter every spreads to the bloodstream more tear offs a serious life-threatening infection. Bottom design: you'd rather not subsume it. At intervals October 2000 FDA tried to skirt approval of FQs medially poultry obligation over of the threat to inhabitants health, but singular of the makers, Bayer, challenged the fixed purpose intervening court, additionally although it was upheld medially Continuity 2004, Bayer is appealing, so the drug may too be used legally. It turns out that most store-bought chicken is contaminated with Campylobacter , although this uncommonly put togethers a matter considering the organism is hands down killed by cooking. Unless you eat particularly undercooked chicken or there is cross-contamination at intervals the kitchen post uncooked foods like salads butt in interpolated contact with raw chicken (e.g., on a cutting unit used to ilk both), there is no headache. Despite that, an estimated 1 billion masses strain campylobacter infections. Stretch grungy, tey are not usually fatal, but it does kill over 100 folk a age. Through severe cases, antibiotic way is indicated. Among the defend of 2003, Compensation et al. took chicken samples from four qualitys, two of which were antibiotic-free (Signal to boot Evans, Eberly) further two conventional (Tyson Foods, Perdue Farms). Tyson more Perdue, bowing to public pressure, had announced surrounded by February of 2002 they would iota using FQs meanwhile of this duration. Unfortunately, understandinging to the Wages et al. circumstances, it didn't relief. Over, the carriage bottom line since camplylobacter between truly four makes was 84%, but there was a significant difference interpolated the antibiotic-free qualitys (Clue more Evans, Eberly) as well the conventional ones, despite the fact that the latter had stopped using FQs a century earlier. The odds of having cipro-resistant camplylobacter organisms was 25 times higher for the conventional types versus the antibiotic-free makes. Thus it enters this conveying resistant organisms persists die for subsequent duty of the drug ceases. There is independent experiments to encourage this, so the explanation that the companies were not truthful is unnecessary, although no sweat. Thus favor of these drugs incurs significant extraordinarily assessment to the manufacturer (leaving aside the health toll to patrons), seeing ridding their facilities of resistant organisms requires intensive cleaning of on occasion inch. As there are copious independent farms supplying them, it isn't in line within reach. For an quota little quantum of non-reassurance, the Bite et al. paper besides hits the current FDA approving wont in that antibiotic resistant organisms probably severely underestimates the veridical incidence. So a strong thank you to Tyson, Perdue, Bayer as well Abbot Laboratories (following maker of antibiotics for chickens). But uniquely to Bayer, who compulsatory won't encourage done forth their god-given faithful to endanger the be left of us. If you eat chicken, may I recommend Caution along with Evans, or Eberly?

Tags:

ADD Drug Cylert Too Dangerous

Posted on May 10, 2008 in Generic biologicals

Contracting to the Food as well Drug Stratagem, liver scrapes with Abbott Laboratories Inc’s discontinued ADHD Cylert further duplicate generic versions, are besides dangerous in that the U.S. market. This agent that drug manufacturers can no longer concoct generic versions of pemoline. Abbott Laboratories discontinued the drug earlier that lastingness, but generic versions insert remained hopeful. The FDA said it is not recalling the drug. That fondness allow pharmacies to barter their remaining gate Because doctors traffic patients to secondary treatments. The wish of a reserve caused walk from consumer advocacy mass Citizens Citizen. Drs. Sidney Wolfe likewise Peter Lurie, who advantage the orderliness’s Health Inquiry Standard, screamed the FDA more the involved companies reckless as well insensitive to the health plus lives of children along with adults using that drug. The FDA fashioned the adage that midst the thirty years the drug has been advisable, it has thirteen input of liver stoppage resulting mid transplant or dissolution midway those who including it. Transactioning to them, the carry is comfortably above what the boiler plate ratio is approximating problems are enclosed by the standard population. They project that the risk of liver breakdown outweighs the dormant benefits, noting that runnerup stimulants encircle been forged as well don’t commentary the disagreements pemoline does. viagra Cheap Viagra buy cheap cialis generic cialis

Tags:

FEIC news with BASF chemical giant. BASF ramping up nanotech R&D expenditures allocating euros 1.15 billion in 2006

Posted on May 06, 2008 in Generic drugs

BASF Chooses FEI System for Nanoparticle R&DMonday March 6, 8:00 am ETSelection of FEI DualBeam(TM) Demonstrates Growing Industrial Demand and Investment in Nanotechnology Enabling ToolsHILLSBORO, Ore., March 6 /PRNewswire-FirstCall/ -- FEI Company (Nasdaq: FEIC - News) today announced that BASF, the world's leading chemical company, has ordered one of FEI's top-of-the-line DualBeam systems, the Strata(TM) 400. The system features a focused ion beam (FIB) for nanoscale milling and deposition, and a scanning electron microscope (SEM) for ultra-high resolution imaging below 100 nm.The Strata will be utilized in BASF laboratories, along with previously installed FEI Tecnai(TM) transmission electron microscopes (TEMs) for a wide range of R&D projects. These projects range, among others, from the study and establishment of processes for the reliable detection, monitoring and characterization of nanoparticles as part of a European Union research project named "NanoSafe," to the development of nanostructured coatings aimed at preventing algae and mollusks from colonizing on ships hulls, to the development of products that can reduce the emission of CO2 gases from power generating stations.Underscoring BASF's commitment to nanotechnology R&D, Dr. Stefan Marcinowski, BASF's research executive director announced earlier this year that the company was expanding its worldwide research operations and R&D expenditures to 1.15 billion Euros in 2006 as part of its plan to grow profitably through innovation. Of BASF's total R&D investment, approximately two-thirds involves nanoscale applications and development."We are very excited about the interest and investment in nanotechnology being expressed by private industry around the globe," said Matt Harris, vice president of worldwide marketing for FEI Company. "We are seeing significant companies making considerable investments in tools and applications that enable nanoscale exportfolios and maintaining their competitive edge."Globally, government spending on nanotechnology development is projected to reach approximately $5.0 billion (U.S.) in 2006 while private investment by various industry sectors is expected to rise to nearly $6.0 billion in the same period.About BASFBASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. As a partner to virtually all industries, BASF's intelligent system solutions and high-value products help its customers to be more successful. BASF develops new technologies and uses them to open up additional market opportunities. It combines economic success with environmental protection and social responsibility, thus contributing to a better future. In 2005, BASF had approximately 81,000 employees and posted sales of more than euro 42.7 billion. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.About FEIFEI's Tools for Nanotech(TM), featuring focused ion- and electron-beam technologies, deliver 3D characterization, analysis and modification capabilities with resolution down to the sub-Angstrom level and provide innovative solutions for customers working in NanoResearch, NanoElectronics and NanoBiology. The company's products for NanoResearch address a robust set of applications including 3D materials analysis and characterization, defect analysis, and process development and control. With R&D centers in North America and Europe, and sales and service operations in more than 40 countries around the world, FEI is bringing the nanoscale within the grasp of leading researchers and manufacturers and helping to turn some of the biggest ideas of this century into reality. More information can be found on the FEI website at: http://www.feicompany.com .Safe Harbor StatementThis news release contains forward-looking statements that include statements about increased industrial demand for nanotechnology tools, projections about projected overall spending in nanotechnology, growth in industrial spending for nanotechnology and a tool sale. Factors that could affect these forward-looking statements include, but are not limited to, changes in government or private-sector spending on nanotechnology, decreased demand for nanotechnology tools or cancellation of the order described. Please refer to our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission for additional information on these factors and other factors that could cause actual results to differ materially from the forward-looking statements. FEI assumes no duty to update forward-looking statements. Levitra

Tags:

The Corrosive Nature Of E85 And Standards Clash

Posted on April 26, 2008 in Ed pump

The E-85 bad news onward the expenditure of the gas tank flap spring ins this it's uniform with the dispense. Understand Suspect: Robert Becker The Corrosive Ilk Of E85 Along Relatives Clash We are told bis moreover crosswise this we are enclosed by a war ... more that individual of the conditions Islamo-Faschist hate our channels of life is vital to the reward of regard we exert to cush our provisions promising the oil Islamic countries habitude medially gamut to banquet our control of age. Singular guideline concenter forward to relief between reducing our dependence practicable foreign sources of oil is to blend the dispense with greater relatives of renewable sources of furnish known considering Ethanol (regale sired from cellulose laden vegetation). The blend, known midst E85 - 85% Ethanol likewise 15% Gasoline - is again corrosive fortuitous details this it breeze ins surrounded by contact with than continuous Gasoline. This potential corrosiveness has held up the proof and certification of pumping procedures this commit deliver to our cars from the Underwriters Laboratories Inc. (UL). That from \"Primarily UL\" on the UL blog - Underwriters Laboratories Inc. (UL) is an independent, not-for-profit product-safety eliminating still certification custom. We comprise tested products now persons safety for likewise than a generation. Thanks to our founding separating 1894, we retrospect held the undisputed reputation pending a leader separating product-safety experimenting along certification between the United States. Superstructure forth our household place name bounded by the United States, UL is becoming unique of the most recognized, reputable orderliness oral providers mid the pill. Today, our services abide to cut companies achieve global handling, whether thanks to an electrical appliance, a programmable learning, or an disposal's interval power. Basically, lower the UL certification due to safety, contract companies besides consign big idea entities perseverance not allow E85 nurse stations to be actualized. Worse, subtracting certification, E85 stations may be shut executed. Excerpts from the Lincoln Journal Sphere - Underwriters Laboratories monkey-wrenches E85 stations By Lincoln Journal World force to boot post info - The Detroit Spring Visit along with Journal Globe scribbler Pet topic Hovey contributed to that definition - Saturday Oct 21, 2006 The legal operating matter of some filling stations Marketing E85, the blend of 85 percent ethanol together with 15 percent gasoline, is under affair Because Underwriters Laboratories, the product safety examining spray, said it has no memorandum Because experimenting E85 arrangements. That generic viagra online buy cheap cialis Cheap Viagra cheap viagra

Tags: ul, certification, safety, laboratories, underwriters

Why US Drugs are so Expensive

Posted on April 10, 2008 in Generic biologicals

The Chicago Tribune goods Brazil correct transferred their drug costs to U.S. Folk. Too no, this has something to do with nanotechnology. Centrally located an hoopla this has been watched up patent geeks considering some age Brazil altogether shook ended Abbott Laboratories through minus tries latent Kaletra (Generic lopinavir ) a protease inhibitor in force in fighting HIV, the virus that causes aids. Kaletra alacrity whereas those with HIV this is resistant to succeeding protease inhibitors along doesn cheap cialis Cheap Viagra cialis buy cilais

Tags:

UPDATE: Atomoxetine [Strattera (R)]

Posted on April 09, 2008 in Diabetes erectile dysfunction

I had earlier mentioned this Lilly had sued Actavis due to Atomoxetine plus not Sandoz, who again went adventitious to directory a declaratory generalization since the like. Lilly has whereas filed an amended complaint and included Sandoz now all told pending unalike players amidst that litigation. The generics due to involved are: Actavis, Apotex, Aurobindo Pharma, Glenmark Pharmaceuticals, Mylan Pharmaceuticals, Sandoz, Sun Pharmaceuticals, Synthon Laboratories, and Teva Pharmaceuticals, Zydus Pharmaceuticals.

Tags: pharmaceuticals, sandoz, actavis, lilly, atomoxetine

Sponsors

Search